Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccine
Mesothelin is new target for immunotherapy of mesotheliomas
September 5th, 2004
Mesothelin is a new target for immunotherapy of mesotheliomas. According to a study from the United States, "Mesothelin is a differentiation antigen present on normal mesothelial cells and overexpressed in several human tumors, including mesothelioma and ovarian and pancreatic adenocarcinoma. The mesothelin gene encodes a precursor protein that is processed to yield the 40-kDa protein, mesothelin, attached to the cell membrane by a glycosylphosphatidyl inositol linkage and a 31-kDa shed fragment named megakaryocyte-potentiating factor. The biological function of mesothelin is not known." "Mesothelin is a promising candidate for tumor-specific...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
